BRPI1013893A2 - uso de tetraidrobiopterina como um marcador e um agente terapêutico para a doença de fabry. - Google Patents
uso de tetraidrobiopterina como um marcador e um agente terapêutico para a doença de fabry.Info
- Publication number
- BRPI1013893A2 BRPI1013893A2 BRPI1013893A BRPI1013893A BRPI1013893A2 BR PI1013893 A2 BRPI1013893 A2 BR PI1013893A2 BR PI1013893 A BRPI1013893 A BR PI1013893A BR PI1013893 A BRPI1013893 A BR PI1013893A BR PI1013893 A2 BRPI1013893 A2 BR PI1013893A2
- Authority
- BR
- Brazil
- Prior art keywords
- tetrahydrobiopterin
- marker
- therapeutic agent
- fabry disease
- fabry
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
- Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16815009P | 2009-04-09 | 2009-04-09 | |
PCT/US2010/030552 WO2010118330A2 (en) | 2009-04-09 | 2010-04-09 | Use of tetrahydrobiopterin as a marker and a therapeutic agent for fabry disease |
US12/757,420 US8410101B2 (en) | 2009-04-09 | 2010-04-09 | Use of tetrahydrobiopterin as a marker and a therapeutic agent for fabry disease |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI1013893A2 true BRPI1013893A2 (pt) | 2016-04-05 |
Family
ID=42934560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1013893A BRPI1013893A2 (pt) | 2009-04-09 | 2010-04-09 | uso de tetraidrobiopterina como um marcador e um agente terapêutico para a doença de fabry. |
Country Status (10)
Country | Link |
---|---|
US (1) | US8410101B2 (pt) |
EP (1) | EP2416776A4 (pt) |
JP (1) | JP5463410B2 (pt) |
KR (1) | KR20120022849A (pt) |
CN (1) | CN102387803A (pt) |
AU (1) | AU2010233147B2 (pt) |
BR (1) | BRPI1013893A2 (pt) |
CA (1) | CA2756272A1 (pt) |
MX (1) | MX2011010565A (pt) |
WO (1) | WO2010118330A2 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110217288A1 (en) * | 2010-03-05 | 2011-09-08 | Baylor Research Institute | Involvement of Androgen/Androgen Receptor Pathway in Fabry Disease |
US10047386B2 (en) | 2011-10-11 | 2018-08-14 | The Regents Of The University Of California | Biomarker for abdominal aortic aneurysm |
KR101913199B1 (ko) * | 2016-03-18 | 2018-10-31 | 울산대학교 산학협력단 | 파브리병 진단용 바이오마커 및 이의 용도 |
US11335461B1 (en) | 2017-03-06 | 2022-05-17 | Cerner Innovation, Inc. | Predicting glycogen storage diseases (Pompe disease) and decision support |
US11923048B1 (en) | 2017-10-03 | 2024-03-05 | Cerner Innovation, Inc. | Determining mucopolysaccharidoses and decision support tool |
CN114814063A (zh) * | 2022-04-08 | 2022-07-29 | 宁波熙宁检测技术有限公司 | 一种检测人体内四氢生物蝶呤的方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5925323A (ja) * | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
US6544994B2 (en) * | 2000-06-07 | 2003-04-08 | Eprov Ag | Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase |
JP4251485B2 (ja) * | 2003-08-20 | 2009-04-08 | 生化学工業株式会社 | 糖脂質の測定法、疾病検出方法及びキット |
CA2543315A1 (en) | 2003-11-13 | 2005-06-02 | The General Hospital Corporation | Methods for treating pain |
US7297810B2 (en) * | 2004-12-30 | 2007-11-20 | 3M Innovative Properties Company | High refractive index monomers for optical applications |
KR100759716B1 (ko) * | 2006-09-26 | 2007-10-04 | 고려대학교 산학협력단 | 복합기능 자성체 코어 - 반도체 쉘 나노 입자 및 그의제조방법 |
EP2102660A1 (en) | 2006-12-21 | 2009-09-23 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Diagnostic marker for fabry disease |
WO2008075957A1 (en) * | 2006-12-21 | 2008-06-26 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Treatment of fabry disease |
-
2010
- 2010-04-09 KR KR1020117025920A patent/KR20120022849A/ko not_active Application Discontinuation
- 2010-04-09 AU AU2010233147A patent/AU2010233147B2/en not_active Expired - Fee Related
- 2010-04-09 BR BRPI1013893A patent/BRPI1013893A2/pt not_active Application Discontinuation
- 2010-04-09 CN CN2010800160689A patent/CN102387803A/zh active Pending
- 2010-04-09 MX MX2011010565A patent/MX2011010565A/es not_active Application Discontinuation
- 2010-04-09 JP JP2012504889A patent/JP5463410B2/ja not_active Expired - Fee Related
- 2010-04-09 US US12/757,420 patent/US8410101B2/en not_active Expired - Fee Related
- 2010-04-09 EP EP10762501A patent/EP2416776A4/en not_active Withdrawn
- 2010-04-09 CA CA2756272A patent/CA2756272A1/en not_active Abandoned
- 2010-04-09 WO PCT/US2010/030552 patent/WO2010118330A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US20100260747A1 (en) | 2010-10-14 |
KR20120022849A (ko) | 2012-03-12 |
AU2010233147A1 (en) | 2011-10-13 |
EP2416776A4 (en) | 2012-09-26 |
JP2012523570A (ja) | 2012-10-04 |
CA2756272A1 (en) | 2010-10-14 |
EP2416776A2 (en) | 2012-02-15 |
MX2011010565A (es) | 2011-10-19 |
AU2010233147B2 (en) | 2012-10-25 |
US8410101B2 (en) | 2013-04-02 |
CN102387803A (zh) | 2012-03-21 |
WO2010118330A2 (en) | 2010-10-14 |
WO2010118330A3 (en) | 2011-03-31 |
JP5463410B2 (ja) | 2014-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013016772A2 (pt) | composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado | |
CL2014003232A1 (es) | Formulaciones y métodos para la administración vaginal de antiprogestinas. | |
BR112013013311A2 (pt) | agente terapêutico de indução de citotoxicidade | |
BRPI0908428A2 (pt) | uso de ranozalina para tratar a dor. | |
BRPI1012116A2 (pt) | composição farmacêutica para o tratamento de doenças cardíacas | |
BRPI0907036A2 (pt) | Conjunto de máscara para fornecer gás para um paciente, e, kit de conjunto de máscara para fornecer um gás para um paciente. | |
ZA201209145B (en) | Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application | |
BRPI0819630A2 (pt) | Montagem de interface de paciente para terapia respiratória | |
BRPI1008498A2 (pt) | Composto, prodroga do composto, medicamento, e, uso de um composto. | |
BRPI0921802A8 (pt) | uso de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor,bem como composição e combinação farmacêuticas os compreendendo. | |
BRPI1009372A2 (pt) | compostos, composição farmacêutica e respectivos usos | |
BRPI1013698A2 (pt) | métodos para tratamento com o uso de terapia de combinação | |
BRPI0719523A2 (pt) | Derivado de espirocetal de tioglicose e uso deste como agente terapêutico para diabetes | |
BR112013014934A2 (pt) | um leito de via férrea de poliuretano, um método de preparação e o uso do mesmo | |
BRPI0917026A2 (pt) | uso de sucralose como agente granulador | |
BR112012028773A2 (pt) | composições farmacêuticas compreendendo hidromorfona e naloxona | |
BRPI1011412A2 (pt) | composição para liberação sustentada de droga compreendendo alutinante geopolimérico | |
BRPI1013893A2 (pt) | uso de tetraidrobiopterina como um marcador e um agente terapêutico para a doença de fabry. | |
IL219888A0 (en) | Pyridine-pyridinone derivatives, preparation and therapeutic use thereof | |
FR2954943B1 (fr) | Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique | |
EP2612914A4 (en) | OLIGONUCLEOTIDE, AND THERAPEUTIC AGENT FOR DYSLIPIDEMIA CONTAINING OLIGONUCLEOTIDE AS ACTIVE INGREDIENT | |
BR112013014189A8 (pt) | composição farmacêutica, uso de um agente de potencialização e uso de uma composição | |
BRPI1011610A2 (pt) | êmbolo para um corpo oco medicinal e corpo oco medicinal | |
BR112015012443A2 (pt) | composição de limpeza, método de limpeza do corpo humano, uso da composição e método para prover limpeza | |
ZA201103516B (en) | Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |